Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thiazolidinediones -- some recent developments.

Michael Stumvoll1

  • 1Medizinische Klinik, Abteilung für Endokrinologie, Stoffwechsel und Pathobiochemie, Eberhard-karls-Universität, Tübingen, Germany. michael.stumvoll@med.uni-tuebingen.de

Expert Opinion on Investigational Drugs
|July 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[A diagnostic maze: Cushing's disease].

Innere Medizin (Heidelberg, Germany)·2024
Same author

The Role of Phosphatidylethanolamine N-Methyltransferase (<i>PEMT</i>) and Its Waist-Hip-Ratio-Associated Locus rs4646404 in Obesity-Related Metabolic Traits and Liver Disease.

International journal of molecular sciences·2023
Same author

Long-term green-Mediterranean diet may favor fasting morning cortisol stress hormone; the DIRECT-PLUS clinical trial.

Frontiers in endocrinology·2023
Same author

Circulating acyl-CoA-binding protein/diazepam-binding inhibitor in gestational diabetes mellitus.

Reproductive biology and endocrinology : RB&E·2023
Same author

Successful weight regain attenuation by autologous fecal microbiota transplantation is associated with non-core gut microbiota changes during weight loss; randomized controlled trial.

Gut microbes·2023
Same author

Prebiotic diet changes neural correlates of food decision-making in overweight adults: a randomised controlled within-subject cross-over trial.

Gut·2023
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Thiazolidinediones improve insulin sensitivity by targeting the peroxisome proliferator-activated receptor-gamma. These drugs show promise for preventing Type 2 diabetes and treating inflammatory conditions.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Thiazolidinediones (TZDs) are established treatments for Type 2 diabetes.
  • Their mechanism involves activating peroxisome proliferator-activated receptor-gamma (PPAR-γ).
  • PPAR-γ regulates genes in various cell types, influencing insulin resistance.

Purpose of the Study:

  • To review the established role, mechanism of action, and therapeutic potential of thiazolidinediones.
  • To discuss their impact on insulin sensitivity and potential in Type 2 diabetes prevention.
  • To evaluate safety concerns and broader applications in inflammatory conditions.

Main Methods:

  • Review of existing literature on thiazolidinedione action and clinical use.
  • Analysis of molecular mechanisms involving PPAR-γ activation.

Related Experiment Videos

  • Assessment of clinical data regarding efficacy and safety.

    • Main Results:

    • TZDs enhance insulin sensitivity by modulating adipose tissue mediators and preventing ectopic lipid accumulation.
    • They may preserve beta-cell function, suggesting a role in Type 2 diabetes prevention.
    • Safety concerns from preclinical studies appear less pressing with clinical use, though hepatotoxicity and fluid retention are noted.

    Conclusions:

    • Thiazolidinediones offer a novel approach to treating insulin resistance and preserving beta-cell function.
    • They hold potential for Type 2 diabetes prevention and management.
    • Anti-inflammatory properties suggest utility in atherosclerosis and inflammatory bowel disease, pending long-term data.